This follows a retrospective study examining possible biologic rationale for the increased incidence of death in AML patients treated with Magro + Ven + Aza on the ENHANCE-3 trial (NCT05079230): data from sequencing of participants bone marrow samples revealed a higher incidence of death in patients with TET2 mutations [27]. The gene discussed is TET2; the disease is acute myeloid leukemia.